Related Experiment Video

Updated: May 27, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Time course of treatment effect of OROS® methylphenidate in children with ADHD

Robert B Armstrong1, C V Damaraju, Steve Ascher

  • 1Janssen Scientific Affairs, LLC, Raritan, NJ 08560, USA.

Journal of Attention Disorders
|November 16, 2011
PubMed

Insights

Osmotic-Release Oral System methylphenidate (OROS® MPH) effectively treated ADHD symptoms in children for over 12.5 hours. The treatment showed a robust effect starting at 1 hour post-dose.

Area of Science:

  • Pediatric Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Methylphenidate is a widely prescribed stimulant medication for ADHD treatment.
  • Understanding the pharmacokinetic and pharmacodynamic profile of OROS® MPH is crucial for optimizing treatment efficacy.

Purpose of the Study:

  • To evaluate the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) in children with ADHD.
  • To determine the onset and duration of OROS® MPH's therapeutic effects in a controlled classroom setting.

Main Methods:

  • Combined data from two double-blind, randomized, placebo-controlled, cross-over analog classroom studies.
  • Children (9-12 years) with ADHD received individualized doses of placebo or OROS® MPH.
  • Evaluated cognitive and behavioral outcomes at multiple time points (0.5 hr pre-dose to 12.5 hr post-dose) using standardized tests.

Main Results:

  • Significant treatment effects of OROS® MPH were observed at all post-dose assessment time points (p < .0001).
  • The therapeutic effect of OROS® MPH demonstrated a rapid onset, appearing by 1 hour post-dose.
  • Adverse events associated with OROS® MPH were consistent with previous findings.

Conclusions:

  • OROS® MPH provides a robust and sustained treatment effect for ADHD symptoms in children.
  • The treatment's efficacy begins within 1 hour of administration and lasts for at least 12.5 hours.
  • These findings support the use of OROS® MPH for long-acting symptom management in pediatric ADHD.
Abstract

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Oppositional Defiant Disorder01:30

Oppositional Defiant Disorder

A persistent pattern of angry or irritable mood, defiant behavior, or vindictiveness characterizes Oppositional Defiant Disorder (ODD). Symptoms must occur over at least six months, involve interactions with individuals beyond siblings, and meet specific diagnostic criteria to be clinically significant. The disorder affects emotional regulation, social interactions, and behavior, often manifesting early in life and influencing long-term development and functioning.
Diagnostic Criteria and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...